A new World Health Organization report has found no adverse health outcomes but rather several medical applications for cannabidiol (CBD), despite U.S. federal policy on this cannabinoid chemical.
Earlier last month the WHO released a preliminary report which stated naturally occurring CBD is safe and well tolerated in humans and even animals, and is not associated with any negative public health effects.
“To date, there is no evidence of the recreational use of CBD or any public health-related problems associated with the use of pure CBD,” the report said. Evidence also suggests that CBD mitigates the effects of THC (whether joyous or panicky), according to this and other reports.
Experts further stated that CBD, a non-psychoactive chemical found in cannabis, does not induce physical dependence and is “not associated with abuse potential.” The WHO report went on to mention that CBD users aren’t getting high on the substance, unlike the THC molecule.
As the cannabis reform nonprofit NORML reported, the WHO is currently considering changing CBD’s place in its own drug scheduling code. In September, NORML submitted written testimony to the U.S. Food and Drug Administration (FDA) opposing the enactment of international restrictions on access to CBD.
The FDA, which has repeatedly declined to update its position on cannabis products despite a large and ever-growing body of evidence on the subject, is one of a number of agencies that will be advising the WHO in its final review of CBD.
Let’s hope that these studies will help influence the FDA’s views and future choices when it comes to CBD & legalizing marijuana.
Below is the summary of the WHO’s CBD report:
Cannabidiol (CBD) is one of the naturally occurring cannabinoids found in cannabis plants. It
is a 21-carbon terpenophenolic compound which is formed following decarboxylation from a
cannabidiolic acid precursor, although it can also be produced synthetically.
CBD can be converted to tetrahydrocannabinol (THC) under experimental conditions;
however, this does not appear to occur to any significant effect in patients undergoing CBD
In experimental models of abuse liability, CBD appears to have little effect on conditioned
place preference or intracranial self-stimulation. In an animal drug discrimination model CBD
failed to substitute for THC. In humans, CBD exhibits no effects indicative of any abuse or
CBD has been demonstrated as an effective treatment of epilepsy in several clinical trials, with
one pure CBD product (Epidiolex®) currently in Phase III trials. There is also preliminary
evidence that CBD may be a useful treatment for a number of other medical conditions.
There is unsanctioned medical use of CBD based products with oils, supplements, gums, and
high concentration extracts available online for the treatment of many ailments.
CBD is generally well tolerated with a good safety profile. Reported adverse effects may be as
a result of drug-drug interactions between CBD and patients’ existing medications.
Several countries have modified their national controls to accommodate CBD as a medicinal
To date, there is no evidence of recreational use of CBD or any public health related problems
associated with the use of pure CBD.